Seventy-five per cent of bladder cancers are superficial at initial presentation, limited to the mucosa, submucosa, or lamina propria. Recurrence rates after initial treatment are 50-80%, with progression to muscle-invading tumour in 10-25%. In muscle-invading bladder cancers, there is a 50% ...
Choose Specialty Benign Conditions Benign Prostatic Hyperplasia Bladder Cancer Female Urology Genitourinary Cancers Genomic Testing Hormone Therapy Kidney Cancer Kidney StonesKidney StonesKidney StonesKidney StonesKidney StonesKidney Stones Men's Health Next-Generation Imaging OAB and IncontinenceOAB and Incontinenc...
With BCG, which is the gold standard of treatment for high-risk non-muscle invasive bladder cancer, unfortunately, we have had shortages in the United States and worldwide. This is also driving trends that we observed, particularly in this study, with increasing use of intravesical gemcitabine a...
“TAR-200 represents a novel interventional approach for the treatment of localized bladder cancer where today, unfortunately, options are limited and include antiquated BCG therapy or radical cystectomy,” said Kiran Patel, M.D., Vice President...
EP: 1.An Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC) EP: 2.Current Standard-of-Care Treatment for Patients With BCG-Unresponsive High-Risk NMIBC EP: 3.Overview of the Mechanism of Action of TAR-200 in Patients With BCG-Unresponsive High-Risk NMIBC EP: 4.Safet...
Patients meeting the criteria for BCG-exposed and BCG-unresponsive NMIBC, as defined by the Food and Drug Administration and International Bladder Cancer Group, were selected. To compare treatment patterns and outcomes, high-risk recurrence occurring more than 24 months after th...
Cretostimogene grenadenorepvec is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase 3 clinical trial for the treatment of BCG-unresponsive Non-Muscle Invasive Bladder Cance...
Despite adequate trans-urethral resection of the bladder tumour (TURBT), non-muscle-invasive bladder cancer (NMIBC) is associated with high rates of recurrence and progression. Instillation of Bacillus Calmette-Guérin (BCG) into the urinary bladder after TURBT (adjuvant intravesical administration) re...
BCG therapy reduces risk of recurrence in superficial bladder cancerdoi:10.1038/ncpuro0491Sole, K.NATURE CLINICAL PRACTICE UROLOGYSole, K. (2006) BCG therapy reduces risk of recurrence in superficial bladder cancer. Nat. Clin. Pract. Urol. 3, 292-293...
Bladder cancer: Confirmation of long-term superiority of adjuvant BCG in both intermediate-risk and high-risk patientsNature Reviews Urology 7, 177 (2010). doi:10.1038/nrurol.2010.30Author ...doi:10.1038/nrurol.2010.30DrakeRebeccaNature Reviews Urology...